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ABSTRACT 
The present study was aimed to isolate p-i,3 Giucan, 
a inner cell wall cooapcment froa compressed bakers yeast, 
Saccharomyces cerevisae. These studies were also carried out 
to evaluate the toxicity in an experimental animal and to 
further assess the adjuvanticity of p-i,3 Giucan, which is 
commonly employed as an immunomodulator in vaccination studies 
against a large number of parasitic infections. In this 
study p-1,3 Giucan was isolated as per modified method of 
Di Luzio et ai (1979) and Hassid et al (1941). The various 
procedures employed for giucan extraction enabled us to 
increase the yield to some extent. The yield of giucan in 
this study was 7A% of the weight of compressed yeast. The 
exact reason for the apparent differences in the yield of 
this product may be due to repetition of some steps and 
certain modifications such as, employing buchner funnel 
fitted with 0.45 Aim Whatman filter paper during filtration 
by suction. 
In this study, after estimating the melting point of 
the isolated giucan as 131^0, chemical analysis was carried 
out for estimating the total carbohydrate contents. The 
carbohydrate contents were estimated as 240 mg/»l. The upward 
mutorotation during hydrolysis indicated a p-configuration of 
glucose units in the polysaccharidic giucan. 
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The potential toxicity i.e. the minimal lethal dose of 
glucan was evaluated by estimating the LO 50 doses. Such 
experiments were considered essential before making any efforts 
to use glucan as a possible immunoadjuvant in vaccination 
studies* several groups of mice were administered with a 
single intraperitoneal inoculation of glucan doses in an 
increasing logarithmic ratio (eg. successively doubled). In 
our study, the data, mortality graph and animal titration 
results clearly indicate that for a mice LD 50 dose was 
greater than 2 g/kg when given intraperitoneally. 
The immunological studies relating to glucan were also 
carried out. The studies carried out to assess the adjuvan-
ticity of isolated glucan, as per a predetermined inaunization 
schedule. The antibody titers were evaluated by IHA and were 
found to be highest with 40 mg/kg dose. 
The results obtained from this study will be helpful in 
our attempts to standardize the glucan preparation, for 
obtaining adjuvant samples with uniform immunobiological 
activity. In vaccination studies, eliminating the problem of 
glucan associated biological variance is of paramount importance. 
In the absence of such data, any further use of glucan in 
vaccination experiments would be an unwise step. The need 
for obtaining consistently uniform results in any future 
- viii -
attempts towards development of an effective vaccine against 
parasitic infections cannot be compromised at any cost. In 
the past, the practice of obtaining glucan from one or two 
laboratories in Europe and United States is no longer going 
to suffice the growing need of this very important adjuvant, 
which is being increasingly used in a large number of 
vaccination studies against various parasitic infections. 
- ix -
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INTRODUCTION 
IflDisunization of man and other animals by a r t i f i c i a l Means 
i s carried out for several dis t inct purposes. The main aim of 
vaccination, whose achievement has already produced enoinous 
benefit to mankind, i s prophylactic immunization against 
infectious diseases - so that long - last ing ef fect ive imaunity 
results from controlled stimulation of the immune system. By 
administering a hazmless vaccine, rather than allowing an 
uncontrolled stimulation by natural /c l inical infection of the 
microbes or parasites, a susceptible host i s encouraged to 
generate adequate immune responses for obtaining a temporary/ 
last ing immunity. A higher concentration of such protective 
antibodies maintained in the circulation help in fighting or 
overcoming a subclinical infect ion. Ideal ly, the effect of 
such a prophylactic immunization must be long las t ing . For 
practical and economic reasons, prophylactic immunization 
needs to be obtained with a minimum number of administrations 
and preferably by a simple infection employing the l eas t 
amount of antigen - compatible with ef f ic ient immunization. 
Ki^ en non-living agents are used some special means, of which 
the use of adjuvants i s the main example, are needed to ensure 
the fulfilment of this requirement. 
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A basic difficulty in any attempt to survey adjuvants 
is that this deceptively simple teim has various meanings* 
An adjuvant substance was defined by early research workers 
as one which stimulated the production of increased levels 
of antibody against protein antigens. This simplistic 
connotation was changed when it was d«aonstrated that in 
addition) adjuvants could stimulate cell mediated (delayed 
type hypersensitivity) or allergic responses against protein 
antigens and autoimmune reactions against homologous or hetero-
logous tissue antigens. Later, adjuvant substances have been 
shown to cause either an increase in the immune response 
(immunopotentiation), or conversely a decrease in the immune 
response (immunodepression). The latter effect diminishes the 
physiologic value of the term adjuvant from the Latin adiuvare 
(to help) and more frequently, these substances are being 
referred to as immunomodulating agents. 
Accomodating all the above views and according to recmt 
discussions (W.H.O. Tech. Rep, series 595, 1976; Elderman R. 
1980), the immunomodulating adjuvants can be defined as 
substances that are incorporated into or injected simultaneously/ 
concomitantly with an antigen. Such substances help in 
potentiating non-specific immune responses. A safe immuno-
modulating agent, in addition to numerous other factors, must 
be able to control the harmful effects of an otherwise active 
substance. An immunoinodulating agent should be able t o increase 
the iaununogenlc potency of vaccines which are poorly loHBunogenic, 
or of r e l a t i v e low molecular mass, or genet ica l ly manipulated 
an t igens . An immunomodulating adjuvant must therefore conform 
to the following a t t r i b u t e s : 
A) I t should not induce hypersens i t iv i ty react ions t o h o s t ' s 
own t i s s u e s or t o i t s e l f . 
B) I t must not contain c ross - reac t ive antigens with human 
t i s s u e s . 
C) I t should not be carcinogenic tera togenic or abortogenic. 
D) I t should not be contaminated with substances t ha t might 
s t imulate other immunological events not involved in the 
speci f ic response. 
E) I t must be biodegradable in human body. 
F) I t must never produce harmful nodules or abscesses i f 
administered intramuscularly (im) or subcutaneously. 
G) I t should not be unstable in the manufactured vaccine for 
a t l e a s t a period of two yea r s . 
The kind of immunostimulation produced by adjuvants 
should be measured and judged in r e l a t i on t o the so r t of use 
for which they are intended* Also, acute and chronic t ox i c i t y 
assay of new candidate immunological adjuvants should be 
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performed in controlled studies with attention to both the 
local and the systemic sites, following both single and 
multiple injections. 
For being clinically useful, vaccines containing 
adjuvants must have a specified shelf-life, for retaining 
useful adjuvant activity during the period and without 
developing properties that would increase adverse reactions. 
Unfortunately, these are indeed harsh conditions to impose on 
the adjuvant researchers, who must be cognizant with the 
biological activities of acceptable adjuvants. 
DIFFERENT TYPES OF ADJUVANTS; 
An astonishing variety of substances has been shown to 
act as adjuvants, but those whidi have found a use in vaccines, 
or which have been major subjects of experimental investigation, 
have been elucidated and discussed here. 
1, Aluminium Salts: 
Aluminium salts have been used particularly to raise the 
immunogenicity of toxoids in the development of antitoxic anti-
sera. The first application of alum as an adjuvant was 
reported by Glenny et al. (1926) who used diptheria toxiods 
precipitated with potassium alum KAl (S04)2»-1-2H20, filtered 
and emulsified with water, in experimental vaccination of 
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guinea pigs. The animals injected subcutaneously with the 
suspension of alum-toxoid precipitate developed iaununity. The 
iaununity generated following such a treatment was measured by 
the onset of negative Schick Test at a much higher rate than 
the controls vaccinated with the original toxoid solution* 
The enhancement of immune response to alum precipitated 
toxoids have a two-fold action: 
!• Providing a large absorptive areas to absort) fairly soluble 
(free diffusable) proteins and limit their biodiffusion. 
2. Providing a particular attraction to immunogen-processing 
(phagocytic) cells in vivo by virtue of their low solubility 
(hydroxide). 
Another important property of the aluminium salts is 
that they are not very toxic to cells mounting the immune 
2 
response, unlike many other metal ions, such as Cu which 
also aggregates or precipitates protein antigens. 
Alum-precipitated vaccines were widely used for immuni-
zation of man and animals. As an alternative to alum 
precipitation, the toxoids are sometimes mixed with preformed 
gels of Al(0H)2 or AlPO.i to which they bind by ionic inter-
action to produce adsorbed vaccines. Aluminium salts thus 
remains the sole adjuvants acceptable for human vaccines at 
the present time. 
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2. S i l ica 
The adjuvant effect of s i l i c a dust consisting of t r i -
dymite, a pseudohexagonal orthorombic form of crystal l ine 
Si02> injected intravenously into rabbits and rats was studied 
following subsequent antibody response of experimental animals 
to ovalbumin by Pernis and Paronetto (1962). The time inter-
val between the administration of adjuvant and that of antigen 
was varied from 0-90 days. The enhancement of the immune 
response measured by the serum antibody levels and the 
number of antibody containing c e l l s in lymphoid organs 
progressively increased with the time interval and reached to 
a maximum at 90 days. This i s in marked contrast to the t in* 
re lat io i sh ip found in immunizations employing other kinds of 
adjuvants where the strongest response usually follows a 
simultaneous application of antigen and adjuvant. The 
s i l i c a treated rabbits exhibited a progressive enlargement 
of spleen and lymph nodes upto 10 times the normal s i z e . 
Thus the injected s i l i c a dust induces extensive proliferation 
of lymphoid c e l l s . Pemis & Paronetto (1962) pointed out 
that antigens adsorbed onto inert particles such as s i l i cates» 
are l ike ly to be ingested by phagocytic c e l l s and provoke a 
foreign body-type macrophage response. Slow release of 
antigen from the local granuloma might allow increased 
stimulation of immunologically competent c e l l s in the regional 
lymph nodes. 
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3» Freund's Adjuvants 
Freund's adjuvants induce powerful cel l-aediated 
responses, humoral inxnunlty, break tolerance and potentiate 
tumour reject ion. Their nomenclature honours the work of 
Jules Freund and his co>workers who established the conditions 
required to obtain reproducible ac t iv i ty , despite relying on 
materials of uncertain composition and of varying physical 
and chemical properties. 
The history of these adjuvants i s briefly outlined by 
Freund (1942, 1945). Towards the beginning of th i s century, 
i t was found that an antigen injected into a tuberculous 
'focus' gave heightened antibody t i t r e s and e l i c i t e d a greater 
degree of delayed hypersensitivity in guinea pigs than wAien 
i t was injected at other (non tuberculous) s i t e s . Further 
more, they showed that heat-ki l led tubercle b a c i l l i gave a 
marked t i s sue reaction, and antigens injected into th i s area 
of inflammation also e l i c i t ed hypersensit ivity. The sane 
antigen injected into acute inflammatory foci produced with 
non-bacterial i rr i tants including s i l i c a , tapioca or turpentine, 
however, did not e l i c i t any greater immune response than upon 
injection into non-inflammatory t i s s u e . This finding led 
Freund and Mc Deimott (1942) to develop adjuvants containing 
mycobacteria, A key constituent of the ir adjuvant formulation 
was a lanolin l ike substance contained in Aquaphor, which i s 
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derived from wool fat and which contains added petrolatum 
hydrocaidbons. 
Further research has shown that adjuvant act iv i ty for 
induction of c e l l mediated ioununity can be obtained also with 
variations frooi the c lass ica l (complete) Freund*s adjuvant 
which consists of dead Mycobacterium suspended in mineral o i l 
with an added emulsifier. Such variations can be achieved by 
(1) using either l i v e or dead bacteria without an oi ly vehicle 
or, (2) by using an oily vehicle without a bacterial component. 
The f i r s t variant has been studied with a view to 
using adjuvant immunotherapy t o treat cancer, with viable 
Bacillus Calmette-^uerin (BCXH), a strain of Mycobacterium bovis 
(Mackaness et a l , 1973) given in sal ine as the sole adjuvant 
material. 
The second variant seems to apply only to the immunization 
of rats , particularly in the context of sensit iz ing an animal 
to develop autointolerance t o i t s own myelinated nervous 
t i s s u e (a l l erg ic encephalomyelitis). For th i s purpose, the 
animals are usually challenged with a crude extract of spinal 
cord as the encephalitogen, a material which may contain 
natural emulsifiers with considerable l ip ids and other intr ins ic 
pro-adjuvant components. As an extrinsic adjuvant i t i s only 
necessdiy to use an oily vehicle which need not be a nineral 
oil (White, 1973). This phenomenon clearly contradicts the 
generally accepted view that it is the bacterial component 
which provides the essential adjuvanticity for cell mediated 
immunity• 
This second varient has been evaluated at some length, 
for it has not always been appreciated that the vehicle may be 
of prime importance in determining the ultimate magnitude of 
an auto-allergic response. It has long been known that 
mineral oil (with or without an emulsifying agent) is an 
adequate adjuvant to stimulate a humoral response to 
simultaneously applied immunogen, and when used for this 
purpose it is commonly described as Freund*s incomplete 
adjuvant, 
Freund*s incomplete adjuvant ( i , e« o i l emulsion 
adjuvants) i s used in veterinary vaccines, but because of i t s 
tendency to cause s t e r i l e abscesses at the s i t e of injection 
i t has been abandoned for human use, 
Freund's complete adjuvant (k i l l ed mycobacteria 
suspended in the o i l ) i s too inflammatory even for veterinary 
vaccines, but i s most ef fect ive for raising high t i t r e 
antibodies in experimental animals* 
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4. Bacterial Lipopolvsaccharid^s (Endotoxins) 
These are toxic principles* usually designated as 
Lipopolysaccharides (LPS)> produced by gram^negative bacteria. 
They are bound firmly to the bacterial cell wall in a coaplex 
with protein, from which they are shed when the cell under-
goes lysis« The texic 'endotoxin* is therefore a misnoner 
because neither these substances originate from outside the 
cells» nor they are always toxic. However* they do show the 
property of increasing resistance to infection, Lipopoly-
saccharides (LPS) when administered by various routes in 
microgram amounts to laboratory animals have been shown to 
elicit early IgM antibody responses (and later IgG responses 
in some species) against the polysaccharide components of the 
lipopolysaccharides. 
The amount of antibody is much greater than that 
elicited by corresponding amounts of the polysaccharide 
component alone, when some other antigens are administered 
in small amounts simultaneously with lipopolysaccharides, the 
antibody response against then is also greatly increased. 
Lipopolysaccharides may therefore be regarded as adjuvants. 
They also have a wide variety of biological activities that 
are not directly related to their effect on the immune respont«. 
These include pyrogenicity, activation of plasminogen, adrenal 
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corticol stimulation, adherence of polymorF^s and platelets 
to vascular endothelium (followed by leucocytosis). They 
further participate in the stimulation of acute phase protein 
synthesis (including properdin) by the liver, interferon release 
and stimulation and activation of the alternate complement 
pathway, Lipopolysaccharide is thought to act on a variety 
of different cells of which polymorphs and macrophages may be 
the most important, since these are the probable source of 
secondarily active factorsCeg» interferon, lysosomal enzymes* 
plasminog^i activator and other neutral proteases and possibly 
lymphocyte - activating factors). 
The biological activities are wholly attributable to 
the presence of lipid A, which is common to all Lipopoly-
saccharides. Lipid A is composed of two molecules of 
p (1.6)«linked glucosamine phosphate, to the amino group of 
which are attached myristic acid, Additi<xial molecules of 
lauric and palmitic acid are attached at positions 3 and 4 to 
one of the glucosamine molecules. Modification of this 
structure by chemical means is possible. Pure lipid A 
aggregates to a viable extent in the presence of divalent 
cations and can only be reliably studied in monomeric fora 
(conveniently as a trimethylamine salt prepared by electro-
dialysis) or as a complex with an inert protein, such as 
bovine serum albumin. 
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Pur« l ipid A i s pyrogenic in primates at a dose of 
O.Oi MQ per kg of body weight, but very nauch larger quantities 
can be administered without proving f a t a l . Tolerance to the 
pyrogenic action i s rapidly produced by repeated administration. 
Although i t s wide spectrum of biological a c t i v i t i e s 
makes i t unlikely that l ip id A would noxxoally be useful as 
an adjuvant, i t i s of interest because i t has been shown to 
be a potent activator of a subset of B-lymphocytes (detected 
in mouse, rabbit or human spleen, but with a variable 
distribution in other t i s s u e s ) . Basically, i t helps B lympho-
cytes to d i f ferent iate , divide and secrete IgM antibodies. 
This results in non-specific activation of the susceptible 
B-lymphocytes, irrespective of the ir antibody spec i f i c i ty . 
Infact , i t increases the proliferation of B>lymphocytes already 
speci f ical ly stimulated by a separate antigen administered 
simultaneously. 
5, Calmette-Guerin Bacillus (B.C.G.) 
B.C.G. a potent immunostimulant is presently the most 
commonly used non-specific stimulating substance in human 
therapy. As an immunostimulant BCXS increases resistance in 
mice to several unrelated bacterial infections and markedly 
enhances the clearance of particulate materials by the reticu-
loendothelial system. Such stimulation persists for a very 
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long period. The BCG enhances the production of antibodies and 
increases the number of spleen antibody producing cells. 
Also it increases delayed type hypersensitivity for particulate 
and soluble antigens, accelerates the rejection of skin 
allografts and transplanted tumours in mice and inhibits 
carcinogenesis. It also tends to modify the action of 
chemotherapeutic drugs such as cyclophosphamide (Mackaness, 
1970). In respect to toxicity the BCX3 may act synergistically 
or antagonistically with certain chemotherapeutic drugs. 
The BCG could help to promote the immunological rejec-
tion of tumours or augment resistance to infection in two ways. 
The immune rejection of tumour depends on the potentiating 
effect that mycobacteria exert on the immune response in 
general. The augmentation of resistance largely depends on 
inducing reticuloendothelial hyperplasia and hyperactivity. 
This is seen not only in animals injected with BCG but also 
when subjects with cell-mediated immunity are deliberately 
or inadvertently exposed to the specific antigen. The first 
effect of BCG also serves to enhance the hosts capacity to 
make a specifically directed attack on the tumour cells or 
the parasite. The second attribute helps in the final 
expression of resistance by creating a more efficient scavenging 
system. The latter seems at present to be as crucial in 
promoting anti-tumour immunity as in augmenting resistance 
to some infectious diseases (Mackaness, 1962). 
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Stimulation of cell-mediated immunity is best achieved 
with a freshly prepared culture of BCG containing a high 
proportion of live bacilli. The mode of preparation and 
preservation on bacterial suspensions and the strains used 
are of importance for the efficiency of BCG adjuvanticity. 
There is evidence that optimum activity depends upon the 
use of bacteria from the pellicle gifowth rather than from 
submerged culture. Killed bacilli act mainly to increase 
circulating antibodies. 
In order to avoid any possible hazards arising from 
the use of strains of live, though attenuated bacilli in 
human subjects, efforts have been made to substitute sapro-
phytic bacteria or to use subcellular fractions of myco-
bacteria. 
6. polynucleotides and Nucleic Acids 
Much of the earlier literature on this subject has 
been reviewed in a book (Beers & Braun, 1971). Originally, 
interest was aroused in these polyphosphates which contain 
the common purines and pyrimidlnes, since it was believed 
that endogenous oligonucleotides formed in some quantity -
after x-irradiation or treatment with cytostatic drugs or 
cell necrotic agents such as endotoxins - were responsible 
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for the heightened (humoral) immune responsiveness observed in 
all these conditions. Concurrent discoveries that these 
substances also induce immunity further helped in generating 
research interest in them. 
Polynucleotides are formed following the action of 
enzyme, polynucleotide phosphorylase, isolated from streptooiyces 
lysodeikticus on the desired mononucleotide diphosphates. 
When the polymerized single strands from opposite base 
pairs are mixed, a double helix is formed. Thus polyadenylic 
acid mixed with its opposite base pair, polyuridylic acid, 
forms the poly A:U complex. Similarly polyinosinic acid mixed 
with polycytidylic acid forms poly I:C complex. 
The potential usefulness of such complexes as immune 
stimulants was suggested initially by the finding of Jaraslow & 
Taliaferro (1956) who indicated that nucleic acid rich tissues 
have a restorative effect in animals rendered deficient in 
antibody forming capacity following irradiation. Subsequently, 
heterologous and homologous CNA and RNA, as well as the low 
molecular weight products, resulting from nuclease treatment 
were shown to act as adjuvants in the normal immune response 
(Merritt & Johnson, 1965). Following advances in the field 
of nucleic acid synthesis, the synthetic polynucleotides became 
available and these likewise, were found as effective adjuvants 
(Johnson, 1976), 
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The polynucleotides have been found t o enhance antibody 
response to many antigens in a var ie ty of maiomalian and avian 
spec ies . Their efficacy as adjuvants i s i l l u s t r a t e d by 
t h e i r capacity t o render proteins in low concentrations of 
iO-i ng an t igen ic . They are a lso found t o be ef fec t ive by 
DQultiple routes and need not be given together with antigens 
(Johnson, 1976). 
Polynucleotides can affect host defence systems, non-
s p e c i f i c a l l y , against a wide spectrum of infect ious agen ts . 
I r r e spec t ive of the mechanisms the potent ia t ion of immunologic 
vaccines by polynucleotides offers promise for the fu tu re . 
This i s pa r t i cu la r ly so for cer ta in v i r a l vaccines, s ince 
t h i s adjuvant ' s a b i l i t y t o render immunogenic antigen concen-
t r a t i o n s in nanograms concentrat ions may abrogate the need 
fo r amounts of purif ied vi rus mater ial d i f f i c u l t t o achieve. 
7 . Muramyl p i peptide (AADP) 
Approximately ten years ago, synthesis of N-ace ty l -
muramyl-L-alanyl-D-isoglutamine (muramyl dipeptide orMDP), 
representing the copy of a peptidoglycan fragment present in 
bac t e r i a l ce l l walls was achieved by Lederer (1974) and 
Kotani (1975). Development of t h i s new agent which i s 
capable of potent ia t ing the antibody production without many 
s ide -e f fec t s i s , t he re fo re , being act ively pursued, several 
17 
hundred synthet ic muramyl peptide der iva t ives or analogues are 
produced in l a b o r a t o r i e s , allowing a good understanding of 
the r e l a t ionsh ip between chefflical s t ruc tu re and bio logica l 
a c t i v i t i e s of t he se molecules (Lederer, 1980). As in the 
case of many iiamunostlinulating agents , s tudies have shown 
tha t MDP may possess a wide spectrun of proper t ies besides 
t h e i r manifest iauaunological capaci ty . These molecules a l so 
have general phanaacological effects including those which 
can be considered as neurophazmacological (Chedid, 1983). 
MDP in the smallest s t ruc tu re capable of including a l l 
the adjuvant a c t i v i t i e s produced by Aitycobacteria in a water-
in-o i l -emuls ion . However, since t h i s powerful combination 
cannot be used, MOP could only be administered t o humans in 
aqueous media. Under these conditions the adjuvant has 
been shown t o augment the humoral antibody response t o several 
an t igens , although i t has been shown to produce ce r ta in s ide 
ef fec ts such as fever (Chedid, 1983), By chemical modifica-
t i o n , i t has been possible t o el iminate these unwanted proper-
t i e s and t o r e t a in i t s immunopotentiating a c t i v i t y . Certain 
l i p o p h i l i c der ivates of MDP have a l so been shown t o increase 
the ce l l mediated immune response even when administered in 
sa l ine (Ca re l l i e t a l . , 1981), They, however, a l so seem to 
produce stronger side effects than most of t h e i r hydrophil ic 
congeneres and presently have not reached the stage of 
18 
clinical trials. The antibody class that an adjuvant can turn 
on is of utmost importance in view of conferring •real' 
immunity, yet paradoxically most studies do not emphasize 
this aspect and generally focus on producing probably unnecessary 
high antibody titres. 
MDP and adjuvant active derivatives can thus enhance 
both specific and non-specific immunity. Moreover various 
constructs containing MDP could also induce a broader spectrum 
of antiviral, non-specific immunity in addition to the 
protection due to specific antibodies. Muramyl peptides 
may also constitute very favourable tools for a better under-
standing of the relationship between the immune and the 
central nervous system. They can therefore represent poten-
tial drugs in the field of veterinary and human medicine. 
8, Glucan; 
Glucan, an ext rac t from the inner ce l l wall of 
^accharomyces cerevisae , has been variously claimed as a 
non-specif ic stimulant of the re t i cu loendothe l ia l systeoi. 
Beta 1,3 linked glucans have been demonstrated in a var ie ty 
of l abora to r i e s t o s ign i f i can t ly enhance huaorai and c e l l u l a r 
immunity. Glucans have been uniformly demonstrated t o 
mater ia l ly modify the i n f e c t i b i l i t y of experimental animals 
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to a wide variety of agents such as bacteria, fungus, virus 
and parasites. Additionaiiy, glucans have been demonstrated 
to significantly alter growth and development of either 
syngenic, allogenic and autochthompus tumours in experimental 
animals as also in a variety of human malignancies. They 
also have, through their ability to modify macrophage function, 
a profound influence on hemopoietic activity of bone marrow 
and spleen. In numerous studies conducted to date, glucans 
have also been demonstrated to effectively function as an 
adjuvant for tumour, viral, bacterial and parasitic vaccines. 
The broad spectrum of immunopharmacological activity of glucanst 
coupled with the end metdbbolite being glucose, projects the 
continued development of these polyglucose immunomodulators 
for therapeutic purposes against a variety of infectious and 
neoplastic diseases* as well as their development as effective, 
non-toxic adjuvants. At the moment, the broad spectrum 
immunopharmacological activities have helped glucan appear 
as an effective adjuvant. The knowledge in this field has 
been ccmprehensively reviewed and discussed in further part 
of this thesis. 
THE POSSIBLE MODE OF ACTION OF ADJUVANTS ON THE IMMUNE RESPONSE 
Some adjuvants exert their effects on a wide range 
of immune responses to an antigen, but in other cases the 
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effects are more or less selective, influencing certain types 
of response rather than others. This could have practical 
application : it is likely, for example that serum antibodies 
play a major role in resistance against certain groups of 
viruses, eg, enteroviruses, whereas cell mediated immunity 
makes an important contribution to host resistance against 
other viruses. If it was possible by the judicious use of 
adjuvants or antigen manipulation to increase the humoral 
immune response elicited by some virus vaccines and the 
cell mediated immune response elicited by others, a 
considerable advance could have been made. Any procedure 
that increases antibody formation rather than cell mediated 
immunity might facilitate the retention of renal allografts, 
whereas the reverse might favour the rejectiwi of tumours. 
Atopic patients would benefit if formation of other classes 
of antibodies, instead of cell-bound sensitizing antibodies, 
could be increased by exposure to antigens in the pres^ice 
of suitable adjuvants. 
Adjuvants can be employed as probes for analyzing the 
subtle cellular interactions wiiich occur during immune responses. 
Antigen doses which in the absence of adjuvants induce specific 
immunological unresponsiveness elicit antibody formation in 
the presence of adjuvants with protein antigens. Incomplete 
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Freund's adjuvant usually s t imulates antibody formation and 
t h i s can block subsequent attempts to induce delayed hypersen-
s i t i v i t y against the same ant igen . Prote in antigens administered 
in Freund's complete adjuvant often e l i c i t cell-mediated 
immunity, affecting the subclass of antibody formed. Possible 
ef fec ts of adjuvants on other systems may also be of b iological 
importance, including e f fec ts on phagocytic c e l l s and on the 
effector c e l l s involved in antibody formation and c e l l mediated 
immunity. 
Eventually, the effects of various adjuvants wil l be 
defined in terms of whether they s t imulate the formatiarj of 
p a r t i c u l a r c lass or subclass of antibody, or c e l l mediated 
immunity. I t i s already c l ea r t h a t a l l adjuvants do not work 
in the same way. In order t o analyze the mode of act ion of 
adjuvants, i t i s essen t ia l to know on which c e l l types in t he 
immune response they exert t h e i r e f f ec t s , d i r ec t ly or 
i n d i r e c t l y . 
ADJ'NfiHT ACTION AT THE CELLULAR LEVEL 
I t has become clear during the l a s t decade tha t the 
immune response usually depends on a complex in te rac t ion 
between antigen and one or more of several c e l l t ypes . The 
p o s s i b i l i t y t h a t contact with antigen can e l i c i t in various 
lymphocyte categories one or the other type of the two 
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mutually exclusive immunological states (immunity and tolerance), 
It is envisaged that adjuvants can act on any one or more of 
the cell types and where operational immunopotentiation is 
observed» there may be stimulation of different combinations 
of these cell types. 
Various substances with empirically defined adjuvftnt 
properties may stimulate macrophages with reference to any 
one of their several roles in immune responses. These 
include: 
(1) The production of processed antigen with increased 
immunogenicity, 
(2) The removal of excess antigen, thereby protecting the 
animal against tolerance induction, 
(3) Improved and/or prolonged presentation of lymphocytes of 
antigen held on their surface membrane, 
(4) Action as cellular reservoirs of antigen that can be 
released over an extended period (it is implicit here that 
repeated stimulation by antigen over an extended period 
will produce higher antibody titres than a single exposure). 
(5) The synthesis and release of (non-specific) lymphocytes-
activating and/or inhibiting factor. 
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Many adjuvants and inunune complexes potentiate the 
trapping of circulatory lymphocytes in drainin'g lymphoid 
organs. This mechanism, which may be mediated by stimulation 
of certain specialized macrophages (littoral cells), 
increases the probability of successful contact between 
all the necessary cellular protagonists in the immune 
response. 
There are a few reasonably well defined model systems 
where an important aspect of adjuvant action is to switch 
cells from a pathway leading towards tolerance to one leading 
to immune differentiations. Both adjuvant action and 
tolerance induction can be at the level of any one or any 
combination of the lymphocyte subtypes such as T (helper), 
T (suppressor), T (killer), B (M^ class) and B ( Y" class). 
Cell differentiation is a time dependent phenomenon and 
it is unequivocal that at least some elements of its mechanisms 
are involved in immune differentiation. Consequently, it is 
of interest that the stimulatory and suppressive effects of 
both adjuvants and immunosuppressive procedures are dependent 
on the timing of their administration (and their doses) in 
relation to that of antigen. A theoretically possible 
mechanism for Certain adjuvants that awaits exploration is 
that they act as selective suppressors of the regulatory 
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T (suppressor ) - c e l l s t h a t are normally e l i c i t e d by an 
administered an t igen . Regulatory mechanisms involving B-cell 
products (ant ibody) , which are stimulated by Freund's adjuvant 
have been demonstrated in Chickens (Vlftiite, 1973)• 
In br ief , i t i s envisaged t h a t adjuvants can act a t 
the c e l l u l a r level in one or more of the following th ree 
ways:-
1) By helping lymphocytes to •decide• to enter a pathway of 
immune ra the r than to le rance d i f f e r e n t i a t i o n . 
2) By amplifying 'post-decision* pro l i fe ra t ion of immune 
induced lymphocytes, e i the r d i rec t ly or via the re lease of 
stimulatory fac tors from macrophages, thereby increasing 
the s i ze of the eventual clones of antibody producing 
c e l l s . 
3) By increasing the efficiency of macrophages for s torage 
and preservation of antigen t o the extent t h a t the spec i f i c 
stimulus i s prolonged, thereby encouraging the ' p o s t -
decision* pro l i fe ra t ion in a d i f fe ren t way. 
This l a s t point serves t o emp*iasize t h a t intermediary 
macrophages may be an important fac to r in many - i f not most -
examples of immune induct ion. 
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ADJUV/\NTS IN ACTIVATION OF MACROPHAGES 
The access of foreign particles to the tissues is 
followed by their engulfment by both microphages (granulo-
cytes) and macrophages. 
Since the latter cells are far more persistent than 
granulocytes in the reactions at the site of a continuing 
infection or invasion by allogeneic or syngeneic cells 
(neoplasm or normal allograft), it commands much greater 
attention from the immunologists, A local inflammatory 
reaction generated by an adjuvant mainly arises from invading 
blood monocytes, although local multiplicati<xi of tissue 
macrophages can also occur. The bulk of ingested materials, 
including bacteria are rapidly broken down in the polylyso-
somes, though significant amounts of materials derived from 
them may be retained in macromolecular form at the macrophage 
surface where they function as potent immunogens. The 
macrophages obtained from recently injected animals exhibit 
enhanced ability to kill and digest such ingested bacilli. 
The various cellular adaptations involved are referred to as 
'activation* and entail the synthesis of large quantities of 
lysosomal and other enzymes, with a variety of end results. 
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EFFECT OF ADJUVANTS ON ANTIBODY CLASSES 
Many adjuvants induce a p re fe ren t i a l synthesis of one 
or more antibody c lasses* The t r igger ing of XgE antibody 
c lass i s pa r t i cu la r ly dependent on the type of adjuvant used 
t o s t imulate the primary response. Both B. pe r tuss i s and 
p a r t i c l e s of AlCOH)^ on which antigen i s adsorbed are very 
e f f i c i en t adjuvants for enhancing the synthesis of XgE 
antibody in rabb i t s and rodents . On the other hand, Freund's 
complete adjuvant favours the synthesis of IgG antibody in 
most spec ies . Mice immunized with a combination of thynus-
dependent antigen such as human serum albumin and B, pe r tuss i s 
produced more IgG^^  and IgG2jjj than IgG2a» Guinea pigs 
immunized with Freund*s complete adjuvant produced IgG. and 
IgG^ an t ibod ies , whereas when the animals stimulated with 
Freund's incomplete adjuvant produce almost en t i r e ly IgG. 
antibody. In t raper i tonea l immunization of rabbi t s with 
alum-precipi tated antigen enhances the production of IgE 
antibody, whereas immunization with Freund*s complete adjuvant 
enhances IgG, 
EFFECT OF ADJUVANTS ON ANTIBODY AFFINITY 
I t has been reported tha t small amounts of antigen 
acting over a prolonged period of time (as in the case of 
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Freund»s complete adjuvant) stimulate the production of 
antibodies against any given determinant whose average 
affinity increases with time. When the antigen is a complex 
molecule possessing a variety of deteiminants, the antibodies 
become more avid as measured, for example, by the capacity 
of an antiserum to form indissociable complexes with the 
antigen. Increase in avidity is explained in part by the 
production of antibodies against more determinants as stimu-
lation is prolonged. The changes in antibody affinity occur 
in antibodies of the IgG class and only to a minor extent in 
those of the IgM class. 
THE DEPOT HYPOTHESIS 
This states that the adjuvant immobilizes the antigen, 
preventing its dissemination from the site of injection, or 
the draining lymph node and causing it to be slowly released 
into the immune system. A slow release of antigen causes 
prolonged antigenic stimulation, and a secondary-type antibody 
response can likely develop. Studies with radiolabelled 
proteins have confinned that the inorganic gels and emulsions . 
do retain the antigen. Also, for both of these adjuvants, a 
good physical association with the antigen is necessary for the 
full adjuvant activity. The immunogenicity of proteins ¥*iich 
do not adsorb to aluminium salts is poorly enhanced by this 
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adjuvant and o i l - in -wa te r emulsions are not nearly as ef fec t ive 
as w a t e r - i n - o i i . 
The depot hypothesis has been challanged on two grounds* 
F i r s t , the excision of the antigen adjuvant depot from a 
subcutaneous s i t e soon a f t e r infect ion does not prevent 
boosting of the immune response. However, these experiments 
do not completely refute the hypothesis because i t i s known 
t h a t complexes of antigen and adjuvant are very rapidly 
d i s t r ibu ted in to the draining lymph node, and may gradually 
r e l ease t h e i r payload, in these t i s sues* The only conclusion 
tha t can be drawn is t h a t the continuing presence of the 
subcutaneous depot which may, i f l e f t undistuiHbed remains for 
weeks or months, i s not requi red , Seccxidly, the re are some 
antigens which are suscept ible to t h e adjuvant act ion of gels 
or emulsions do not provoke any antibody resp>onse when injected 
on t h e i r own in mul t ip le , small doses for obtaining a slow 
r e l ea se . This ind ica tes tha t slow re lease may not by i t s e l f 
be suf f ic ien t to account fo r adjuvant a c t i v i t y , although i t 
may s t i l l be a contributory fac to r in combination with effects 
of the adjuvant on the immune system, 
FACTORS IN ADJUVANT EFFECTS 
Although much remains to be learned about mechanisms 
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underlying adjuvant action, it is already clear that adjuvants 
exert their effects in several more or less distinct ways, 
i) Slow Release 
Slowing the re lease of label led antigen injected 
subcutaneously in wate r - in -o i l emulsion has a half l i f e of 
14 days, while f ree antigen or alum-precipitated antigen has 
a half l i f e of l e s s than one day, the difference in blood 
l eve l s i s hovyever much l e s s marked (Talmage & Dixon, 1953). 
However, antibody response to soluble antigens such as BSA 
or bovine gamma-globulin can be increased by inject ing 
adjuvants a t d i f ferent s i t e s from those of antigen in jec t ion 
(Dresser, 1968). 
Endotoxin was not found t o have any effect on the 
t rapping, re ten t ion and loca l i za t ion of l abe l led serum albumin 
in lymph nodes (Ada et a l , , 1968). All these r e s u l t s make ' 
i t unlikely t h a t the depot effect i s more than a contributory 
fac tor t o the mode of act ion of some adjuvants. 
2 , Antigen Denaturation 
Certain antigens can be denatured or made pa r t i cu l a t e 
by emulsif ication or adsorption onto alum, bentonite or other 
p a r t i c l e s . I t i s well known tha t denatured serum proteins» 
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especially gammaglobulin, tend to be immunogenic, whereas the 
native proteins are tolerogenic (Dresser & Mitchison, 1968), 
Denatured or particulate antigen readily becomes associated 
with membranes of macrophages and other immunocompetent cells 
(eg, dendritiz cell of lymph node and spleen). This may 
facilitate the presentation of antigen to lymphocytes in a 
highly immunogenic form, 
3. fiecruitment of Reactive Cells: 
Histologically, the site of inoculation of Freund's 
adjuvant becomes a granuloma, with infiltration of macrophages, 
lymphocytes and other cells. These cells are exposed to 
a relatively high concentration of antigen locally and in 
the draining lymph node, 
4. Stlmulaticwi of the Proliferation and Differentiation of 
Immunocompetent Cells 
The fact that the lipopolysaccharide is a selective B 
cell mitogen and can exert adjuvant effect through B cells is 
unlikely to be a coincidence, Taub et al, (1970) hav« reported 
that vitamin A, which is an efficient adjuvant but not 
immunogenic, induces blast transformation and proliferation 
of cells in the thymus dependent areas of draining lymph nodes, 
whereas other substances, such as paraffin oil, without adjuvant 
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activity have at most fewer effects on the thymus - dependent 
areas of lymph nodes. The allogenic effect is recognised to 
provide a general stimulus to the proliferation of lymphocytes. 
Hyperplasia of the reticulo:^ndothelial system and the 
proliferation of lymphoid cells in animals treated with 
adjuvants are well known. The combined stimulation of clones 
of lymphocytes by antigen and adjuvant is likely to be greater 
than that achieved single handedly. However, in adjuvant-
treated animals there is an overall increase in synthesis of 
immunoglobulin, not just of specific antibody (Binaghi, 1966). 
The same author found that although Freund's adjuvant in 
guinea pigs causes the production of more V and Y" antibody 
against the injected antigen, the percentage rise in serum -^ 
globulin helps other immunocompetent cells to get stimulated 
by the adjuvant, 
5) Cellular stimulation 
in addi t ion to antibody formation, some adjuvants stimu-
l a t e cell-mediated immunity. The c l a s s i c a l Freund*s complete 
adjuvant f a c i l i t a t e s the development of delayed hypersens i t iv i ty 
against serum protein ant igens , in contras t t o the incomplete 
adjuvant which s t imulates antibody formation but not delayed 
hype r sens i t i v i t y . This switch mechanism may be important, 
especia l ly in r e l a t i on t o tumour immunity. Thus, i t was found 
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t h a t Freund»s complete adjuvant diminishes the number of 
tumors appearing a f t e r in jec t ion of adenovirus type 12 in 
hamsters (Bennan e t a l . , 1967), The type of adjuvant timing 
and route of administrat ion and other factors great ly 
influence the end r e s u l t , 
6) Antibody Dependent Ce l lu la r Immunity 
A new fac tor t o be taken in to consideration i s the 
effect of adjuvants on antibody-dependent cell-mediated 
immunity. The number of ef fec tor c e l l s i s increased by 
Freund's complete adjuvant, the effects of other adjuvants 
s t i l l remains t o be inves t iga ted . This system could be 
involved in immunity against ce r t a in tumours, 
HISTORICAL BACKGROUND RELATIVE TO THE DEVELOPMENT OF GLUCANS 
In early f i f t i e s Prof, N.R, DiLuzio of the Tulano 
Universi ty in New Orleans and h i s colleagues in t h e i r labora-
tory attempted to define the ro l e of macrophages in the 
metabolism of chylomicrons and choles terol and t h e i r possible 
ro l e in the development of coronary ar te ry d i sease . At t h a t 
time the technique employed was to depress the macrophages 
and ascer ta in the consequence using co l lo ida l carbon or trypan 
blue for producing the so ca l led ' re t iculoiandothei ia l 
b lockade ' . The accumulation of dyes and pa r t i cu la t e s in 
macrophage elements might lead t o the assumption tha t these 
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cells are functionally impaired, functional phagocytic data 
indicated narked activation of these cells. Thus the technique 
of reticuloendothelial blockade was found to be extremely 
inappropriate in the evaluation of the contribution of macro-
phages to homeostasis. 
In 1957 Benacerof and sebestyn presented a report on 
the influence of intravenously administered Zymosan, a crude 
S. cerevisae cell wall fraction on macrophage activation, one 
of the findings of this study suggested that there occurs 
a stimulation of macrophages as reflected by phagocytic 
activity, as well as the development of hepatosplenomegaly. 
Employing this initial observation, an attempt was 
made to isolate the active component in zymosan, which related 
to its ability to enhance macrophage function as well as 
induce proliferation of macrophage elements in the liver, 
lung and spleen. The results of the above study published in 
1961 (Riggi & DiLuzio, 1961) indicated that the active 
fraction of Zymosan was Glucan. In fact it was this study 
which ushered, the era of glucan research. Retrospectively, 
the results of such researches over a quarter of a century 
has contributed a lot towards the identification of Glucan as 
an effective immunomodulator for therapeutic purposes. 
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Chiharok et ai» in 1969 subsequently isolated ^-1-6, 
p-1,3 glucan from Lentinus edodes which was later designated 
as lentinan. They also demonstrated lentinan*s influence on 
the inhibition of Sarcoma 180 in allogenic mice, since that 
time a variety of glucan(s) have been prepared from an extensive 
assay of single and multicellular fungi. The role of these 
compounds in enhancing the host resistance to either infections 
or malignancies has now been thoroughly studied. In general, 
most effective immunomodulating polysaccharides of the glucan 
class have been derived from s^ . cerevisiae, L. edodes and 
^. commune. 
ADJUVANT ACTIVITY OF GLUCAN 
In 1963 Wooles and Di Luzio demonstrated in a murine 
model that the administration of glucan is associated with an 
increased vascular clearance of sheep red cells and a 
resulting enhancement of both the primary and secondary inmune 
response. Conversely, the administraticm of methyl palmitate 
which reduces phagocytic events was associated with a profound 
depression of both primary and secondary hemolysin titers. 
These observations of the pivotal role of macrophages in the 
induction of immunity have since been confirmed in different 
laboratories. These studies clearly indicated that it is 
possible to control the fate of particulate antigens and to 
modulate immune responsiveness by agents which influence 
macrof^age behaviour. 
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The adjuvant activity of glucan as demonstrated by 
Holbrook et ai. (1981) further confirmed that glucan upon 
simultaneous inoculation with formalin killed erythrocytic 
stages of Plasmodium berghei induces enhanced degree of 
resistance in mice against subsequent infections with variable 
parasites. The injections of formalin killed erythrocytic 
stages of _P. berghei alone did not produced a similar effect. 
The mice immunized with glucan and dead parasite preparations 
showed 100^ survival following challenge. In contrast, only 
28% of the mice receiving antigen alone survived. These 
studies on glucan and antigen parasites were extended by this 
group to evaluate the effects of Leishmania donovani infections 
using glucan as an adjuvant (CookAHoibrook, 1982; Cook & 
Holbrool^ , 1983; Holbrook & Cook, 1983), Mice were immunized 
by a series of intravenous infections with foiraalin-killed 
L» donovani promastigotes alone, or in combination with glucan. 
The mice which were immunized with dead parasites and glucan 
exhibited resistance against challenge upto 80 days, while 
the injection of promastigotes alone conferred no measurable 
resistance against infection. Moreover they have also reported 
that intravenous, intraperitoneal or subcutaneous administration 
of formalin killed L, donovani promastigotes with glucan would 
confer a significant degree of protection against subsequent 
infection with variable promastigotes. Intramuscular 
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immunization was not effective. 
Additional studies showed the unique adjuvant activity 
of glucan (Ahmad et al. 1980) where a lOOJI^  protection was 
obtained against Entamoeba histolytica infections. In these 
studies glucan was employed as an adjuvant with E.histolytica 
extracts. The glucan-antigen immunized guinea pigs were 
devoid of ulcerative amebic lesions which were so prominent in 
the control groups. It has been reported that glucan is an 
effective adjuvant in enhancing immunity to Babesia microti 
infections (Benach et al., 1982). 
Reynolds et al. (1980) also demonstrated that mice 
given glucan combined with marginally immunogenic doses of 
Venezuelan equine encephalomyelitis vaccine were more resistant 
to virus challenges than mice given Freund's complete 
adjuvant (FCA) plus vaccine, or vaccine alone. Indeed in 
all these studies conducted to date, glucan appears to b« 
more effective and less toxic adjuvant than FCA, The 
humoral immunity evaluated in cynomologus monkeys following 
administration of glucan with Venezuelan equine encephalomye-
litis vaccine was significantly enhanced in contrast to 
vaccine controls. These studies denote that glucan is a 
very effective adjuvant for the induction of humoral and 
protective immunity to certain viruses. 
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The enhancement of anti-viral host defense mechanisms 
by glucan was further extended through observations made by 
Williams and Di Luzio (1980) on the modification of murine viral 
hepatitis (A4HV), In these studies it was observed that maxinuiB 
effectiveness in modifying survival to lethal A<HV challenge 
resulted when glucan was administered prior to, as well as 
after, viral challenge. In contrast to the profound hepatic 
parenchymal cell necrosis observed in control mice, glucan-
treated mice exhibited very limited pathology. The maintenance 
of hepatic structure was associated with minimal alterations 
in plasma enzymes such as SGOT and SGPT vrfiich reflect the 
structural integrity of hepatic parenchymal cells. Like wise 
BSP clearance, which was markedly impaired in control mice 
with hepatitis, was essentially normal in the glucan-treated 
viral infected group. Additionally, control mice challenged 
with MHV A-59 hepatitis showed significant impairement in 
macrophage phagocytic function. In contrast, pretreatment 
with glucan prevented macrophage impairment and resulted in 
a hyperphagocytic state in virus challenged mice. These 
studies along with those on E, coli suggest that maintenance 
of an activated state of phagocytic function, as well as other 
possible macrophage secretory and/or metabolic activities, 
resulted in increased survival and the inhibition of cellular 
injury. Their composite findings denote that macrophage 
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stimulants such as giucan may play a significant role in the 
modification of viral •> induced lesions. 
Extensive studies have also been done (Williams et al., 
1983) to evaluate the influence of intraperitoneal inoculation 
of giucan in E^ , coli induced experimental peritonitis and 
sepsis. In these studies giucan was administered prior to 
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i.p. challenge with 1.0 x 10 JE. coli. Data in these 
experiments indicated an approximately 91% survival in the 
giucan treated group, in contrast to an approximated \.9% 
survival in the control group. The difference in degree of 
sepsis between the control and experimental groups was 
prcxiounced. The control group showed exponential increases 
in the blood level of E. coli throughout the 24 hr period of 
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study with mean level of 2 x 10 /ml in the blood. In 
contrast, the giucan-treated groups, which had identical 
blood levels of ^ , coli at early intervals, were almost 
sterile at later intervals. 
USE OF GLUCAN IN THE DEVELOPMBJT OF VACCINE 
Rapid advances made during the last few years in the 
development of adjuvants have led many to believe that adjuvants 
of practical and commercial value would soon emerge out. 
These hopes however have not yet been realized because some 
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crucial problems of adverse side effects still remain to be sol-
ved. There may be possible problems such as: 
(1) Sensitization to the agent itself or to the common antigens 
between agents and the host or auto-antigens. 
(2) Increased formation of blocking antibodies of suppressor 
cells, 
(3) Toxicity for rayelolymphoid cells or neoplastic transfor-
mation of these cells. 
Infections can be controlled by direct chemotherapy or 
by agents capable of increasing the specific or non-specific 
immune responses of the host. At the present time vaccination 
is the oldest and most successful achievement of clinical 
immunology, still there exists many experimental models 
showing that it is possible to increase natural resistance 
to infections by administrating bacterial products such as 
endotoxins or BCG (Mackaness et al,, 1974). It is clear 
that the opportunity offered by modern biotechnology (mono-
clonal antibodies, genetic engineering, DNA sequencing, 
peptide synthesis, purification methods etc.) will be taken 
advantage of to produce improved vaccines. Indeed many 
antigens have already been prepared by genetic engineering 
(Chanock et al,, 1984), including a hepatitis B surface 
antigen produced by yeast which is currently in clinical 
trials (Hilleman, 1985). 
40 
During the last four years a great deal of efforts 
have been devoted to the designing and production of synthetic 
antigens capable of evoking protective or neutralizing immune 
responses towards pathogens and hormones. These studies heve 
supported the notion that to be inununogenic, a preparation 
has to contain three entities: the antigenic determinants 
which will evoke antibodies specific for the pathogen or 
hormone, a carrier molecule affording suitable presentation of 
these determinants to the immune system and an imaunopoten-
tiating moiety which will augment the response. These 
elements are all present in natural vaccines. 
However natural vaccines also contain other structures, 
in most cases poorly defined, which are useless for vaccination 
and are even capable of inducing unwanted side effects. Thus 
one of the main reasons for developing vaccines is to obtain 
efficient preparations capable of producing high antibody 
titres. 
Focussing on the role of carriers and of adjuvants, 
polysaccharide p-i,3 glucan is a good candidate for utilization 
in vaccine preparations. Glucan as a molecular entity is 
essentially non-toxic while it generates utilizable carbohy-
drates during metabolism. 
The adjuvant activity of glucan in enhancing immunity 
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to protozoan infection has been demonstrated by the studies 
of Holbrook and Cook, 1983 and Ahmad et al. (1980) as described 
earlier. 
In suDunary, extensive experiments which have been 
conducted in a var ie ty of l abora to r ies have indicated t h a t 
p-1 ,3 glucans can be effect ively employed in t he modification 
of inajor microparasi t ic d iseases and tumors. Furthermore, 
the broad spectrum of immunobiological a c t i v i t i e s of glucan 
against microparas i t ic diseases and tumors coupled with the 
observations t h a t glucan can be employed as a very effect ive 
adjuvant for a var ie ty of non-self e n t i t i e s including v i ruses , 
b a c t e r i a , fungi, pa ras i t e s and tumor c e l l s protends the develop-
ment of glucans for prophylactic and therapeut ic purposes in 
both c l i n i c a l and veter inary medicine. 
I t i s a l so projected tha t glucan research e f for t s wi l l 
provide a s ign i f ican t contr ibut ion t o the understanding of the 
processes of infect ion within various hosts and contr ibute t o 
new and more effect ive vaccines, as well as drugs, which 
have the a b i l i t y to i n t e r a c t synerg i s t i ca l ly with a l l current 
modes of therapy. 
ISOLATION OF GLUCAN BY EARLIER WORKERS 
Glucan, a neutra l p a r t i c u l a t e p-1,3 polyglucose fro« 
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the cell wall of S. cerevisiae, was first isolated by Hassid 
et al, in 1941. They took 2700 grams of compressed bakers 
yeast grown on a grain roesh and allowed its digestion in two 
portions in 4 liter flasks. Each flask containing 2 liters 
yeast was reacted with 3^ sodium hydroxide by heating on a 
boiling water bath for four hours. The dark brown alkaline 
digest was allowed to remain at room temperature for one day, 
the supernatant liquid was then decanted and 2 liters of fresh 
3^ sodium hydroxide was added to each flask. The flasks 
with the contents were shaken, placed for two hours on a 
boiling water bath and then allowed to cool overnight. The 
alkaline supernatant liquid, which again became dark brown 
was decanted, the residue acidified with about 800 cc of 
concentrated hydrochloric acid and 2 litres of 3% hydrochloric 
acid added to each flask. The flasks with the contents were 
digested for several hours on a water bath, then the super-
natant liquid was cooled, decanted and digested with 351^  
hydrochlozic acid* The final acid digest was decanted, the 
residue washed with distilled water and centrifuged, followed 
by resuspension in water and centrifugation. The residue was 
then washed well with boiling water, centrifuged and the 
combined residues from the two flasks suspended in 1 liter of 
alcohol and stored at room temperature for several days. The 
brownish-red alcohol solution was centrifuged off, the residue 
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(suspended in alcohol and then filtered by suction) was washed 
with ether and dried at 70°c in vaccum for four hours. It was 
allowed to dry into a homy hard brownish mass, then after 
grounding it to a fine powder in a ball mill a grayish white 
powder was obtained. The yield was 6A%t since the moisture 
content of the compressed yeast averages around 70^. 
A modification of the method of Hassid et al. (1941) 
was earlier reported by Di Luzio et al. (1979) to prepare 
particulate glucan from s. cerevisae . The Di Luzio*s 
modified procedure is discussed briefly as follows: 
Using a 6 liter flask 540 g of dry yeast was suspended 
in 3 litres of 3% aqueous sodium hydroxide solution. The 
suspension was placed in a boiling water bath for 4 hrs, cooled 
overnight and the supernatant decanted. This procedure was 
repeated three times. The residue was then acidified with 
300 ml of concentrated hydrochloric acid plus 2 1 of 3?^  
hydrochloric acid and placed in a boiling water bath for 
4 hrs. The suspension was allowed to stand over night and 
the supernatant decanted. The residue was further digested 
with 3 1 of 33S hydrochloric acid at 100*^ 0 for 4 hrs, cooled 
overnight and decanted. The 2% hydrochloric acid digestion 
was repeated twice. The residue was then washed three times 
with distilled water. One litre of ethyl alcohol was added 
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to the residue, mixed thoroughly and allowed to stand for until 
24 hrs for maximum extraction. The dark reddish brown alcohol 
supernatant was aspirated from the residue and discarded. 
The alcohol extraction procedure was repeated twice. The 
alcohol was removed by washing the residue with distilled 
water. The preparation was then collected by centrifugation. 
The residue was light brown in colour. The yield was 6.3J^  of 
the weight of dry yeast. 
In 1973 Manners et al. also made an attempt to extract 
glucan from the cell-wall of baker's compressed yeast. 
About 2 kg yeast was first dispersed in 1.6 litres of 651^  (w/v) 
NaOH and stirred at room temperature for 24 hours. Distilled 
water (12 litres) was then added and the insoluble material 
collected by centrifugation at 1200 g for 14 min. This 
material was suspended in 3 litres of 3% (w/v) NaOH and heated 
at TS'^ C for 3 hrs, then allowed to cool and the suspension was 
stirred for 16 hrs at room temperature. 
After dilution with 3 litres of distilled water the 
insoluble material was again collected by centrifugation at 
1200 g for 15 min. The residue was extracted again with hot 3^ 
NaOH, adjusted to pH 4.5 (with HCl) and collected by centri-
fugation. The insoluble cell wall material was washed thrice 
with water, once with ethanol and twice with ether. The residue 
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was l i g h t brown in colour. On drying in a i r a t 37*^c, the yield 
was 47,9 g or 2,4% of the weight of compressed yeas t . 
In 1958 Peat e t a l , a lso i so la ted glucan from fresh 
baker ' s yeas t . About 6 kg of fresh baker ' s yeast was dispersed 
in 5 l i t e r s of 6% (w/v) NaOH and s t i r r e d a t 75^c for 24 h r s . 
About 14 l i t r e s d i s t i l l e d water was then added and insoluble 
material was co l lec ted by centr i fugat ion a t 1200 g for 15 min. 
This whole mater ial was then suspended in 6 l i t e r s of 0,5 M 
o 
ace t i c acid a t 90 C for 3 h r s . After cooling, the supernatant 
was centrifuged. The residue was washed with water in a 
centr i fuge, then suspended in 0,02 M sodium ace ta te (pH 7 .0 , 
o 2 l i t . ) and heated for 1 hr a t 135 C in an autoclave. After 
cooling, 2 l i t . of water was added and the residue separated 
in a cent r i fuge . The supernatant gave an intense red colour 
with iodine, indicat ing the ext rac t ion of glycogen. After 
s ix washings of the residue with water (1 .5 l i t , each) the 
wash-liquid was achronic, but on fur ther autoclaving a t 
135^0 in 3 l i t , of water extracted more glycogen. The 
residue was therefore centrifuged, washed th ree times with 
water (2 l i t , each) and again autoclaved. The gelat inous 
sol id was dehydrated with ethanol (3 v o l , ) , centrifuged and 
washed successively with ethanol , e ther and l i g h t petroleum. 
The product (39 grams) was a l i g h t buff-coloured powder. 
The t o t a l y ie ld was 0.65% of the weight of fresh bakers yeas t . 
A . I J M [ S i 8 . O B k J E I C I T I ' V E I S 
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AIMS AND OBJECTIVES 
The present study was aimed to isolate p-i,3 Glucan, 
a cell wall component from compressed bakers yeast 
Saccharomyces cerevisae. These investigations were also 
carried out to evaluate the toxicity of glucan in an experi-
mental animal model and to further assess its adjuvanticity. 
Currently, ^-lf3 Glucan is commonly employed as an immuno-
modulator in vaccination against a large number of parasitic 
infections, A detailed plan of the above study was as follows: 
1) p-1,3 Glucan was isolated and purified from compressed 
bakers yeast (S. cerevisae) to get a good yield by 
employing different modifications in the procedures 
already described* 
2) Qhemical characterization of isolated ^1,3 Glucan, 
3) Toxicity studies of the isolated glucan in mice and the 
determination of LD 50 values, 
4) The immunological assays for determining Glucan's adjuvan-
ticity were carried out by means of IHA tests for estimating 
the maximum antibody titer following immunization of test 
animals with different doses of glucan. 
As a short term objective, the study was designed to 
obtain sufficiently large amounts of p-1,3 Glucan for further 
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use in vaccination studies - as also for its possible uses 
in any future attempt towards development of an effective 
vaccine against parasitic infections such as Amoebiasis, 
Leishmaniasis etc. 
M[A.'rE:Ft I A^I^S. 
48 
MATERIALS 
1 . Animals 
About iO-i2 weeks old healthy mice weighing approximately 
12-15 grams employed in t h i s study were obtained from 
M/S Laboaids, Meerut. The rabbi t s employed in t h i s study were 
a lso purchased from the same company. 
2 . Animal Food 
Pellet diet for experimental animals was obtained from 
M/s Hindustan Lever Ltd., India. 
3. Yeast (Saccharomvces cerevisae) 
Compressed cakes of l i v e bakers yeas t , each weighing 
about 500 gms were obtained from M/S Bio-Food Pvt , L td . , Ind ia . 
4 . Anticoagulant 
3.8^ sodium citrate was used as an anticoagulant, 
5 . Preservat ive 
Sodium azide was purchased from Riedel , Germany, 
6. F i l t e r paper 
Whatman f i l t e r paper of pore s ize 0.45 jum was obtained 
from In te rna t iona l Traders, Delhi , 
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7, Chemicals 
Analytical grade potassium phosphate (monobasic), 
potassium phosphate (dibasic), sodium citrate, sodium carbonate, 
sodium chloride, copper sulphate, sodium potassium tartrate, 
sodium hydroxide, sodium hydrogen phosphate, phosphoric acid, 
lithium sulphate, sodium tungstate, sodium molybdate, glucose, 
magnesium chloride, hydrochloric acid, phenol, calcium 
chloride, sulphuric acid were purchased from B.D^H. (India), 
Tannic acid was purchased from w*J. Bush & Co., England, 
Methanol, Ethyl alcohol and solvent ether from Merck & Co, 
Ltd., (India) and bovine serum albumin was purchased from 
Sigma Chemical Co,, U.S*A« 
ryi E I T M O ID S 
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METHODS 
i. ISOLATION OF YEAST GLUCAN 
Particulate glucan was prepared from compressed bakers 
yeast, S. cerevisae, by a modification of the method of 
Di Luzio et al. (1979). Since our modification of the method 
has not been published, the procedure is briefly described 
below: 
About 540 grams of compressed bakers yeast was suspended 
in a 6 liter flask with 3 liter of 6JI^  (w/v) aqueous sodium 
hydroxide solution. The suspension was placed in a boiling 
water bath for 4 hours, cooled overnight and then the dark 
brown supernatant was decanted. The insoluble material was then 
collected by centrifugation at 1200 g for 15 minutes. This 
procedure was repeated twice. The residue was then suspended 
in 3 liter of 3% (w/v) aqueous sodium hydroxide solution. The 
suspension was placed in a boiling water bath for 4 hours then 
allowed to cool. The suspension was stirred for 16 hours at 
room temperature. After dilution with 2 liter of distilled 
water, part of supernatant was decanted and the insoluble 
material was again collected by centrifugation at 1200 g for 
15 min. This procedure was also repeated twice. The residue 
was then acidified with 300 ml of concentrated hydrochloric 
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acid plus 3 liter of 3% hydrochloric acid and placed in a 
boiling water bath for 6 hours. The suspension was allowed to 
stand overnight and the supernatant was decanted. The residue 
was further digested with 4 liter of 3% hydrochloric acid at 
iOO*^ C for 4 hours, cooled overnight and decanted. The residue 
was washed six times with distilled water (20°c) and twice 
with distilled water at iOO°c. Two liters of ethyl alcohol 
was added to the residue, mixed thoroughly and allowed to 
stand for a period of 48 hours for maximum extraction. This 
suspension was then filtered through a buchner funnel fitted 
with a Whatman filter paper of pore size 0,45 Ajun, The dark 
reddish brown alcohol filtrate was discarded. The residue was 
than suspended in ether and filtered through buchner funnel 
with 0,45 Aim Whatman filter paper while the filtrate was 
discarded. The light brown residue was suspended in 2 liter 
ethyl alcohol and again filtered through buchner funnel with 
0,45 Am Whatman filter paper by suction. The above process 
for obtaining alcohol supernatant was repeated until the 
alcohol supernatant was essentially colourless. The alcohol 
was removed by washing the residue four times with hot water. 
The light brown coloured particulate giucan preparation was 
then collected by centrifugation and suspended in 5% (w/v) 
dextrose. The particulate giucan was diluted to the desired 
concentration from stock solutions, placed in injection vials 
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and sterilized by autoclaving for 20 min. at 15 lbs. pressure 
and 120°c. 
2. DETERMINATION OF MELTING POINT 
Determination of melting point of solids plays an 
important role in the identification of organic compounds, A 
pure organic substance has a sharp melting point and the 
change from the solid to liquid state takes place within a 
range of l^c. Presence of even a trace of impurity materially 
influences and lowers its melting point. 
Thiele's method is generally used for determining the 
melting point of organic compounds, A small quantity of the 
organic substance is dried and finely powdered on a porous 
plate and introduced into a thin walled capillary tube about 
two inches long and sealed at one end. The solid is introduced 
into the capillary tube by first introducing the open end of 
capillary tube in the powdered compound, when some of it 
enters the capillary tube then the sample is carefully tapped 
to the end of the porous plate. The process is repeated two 
or three times so that the height of compound in the capillary 
is about half a centimeter. 
In this experiment, the apparatus consisted of a 50 c.c. 
wide mouthed test tube containing cone, sulphuric acid and 
53 
fitted with a thermometer through the length of the cork. 
Then the bulb of the thermometer was moistened with conc» 
sulphuric acid and the capillary was placed close to the 
thermometer in such a way that the solid portion in the 
capillary was sticking to the bulb of the thermometer. The 
thermometer along with the capillary tube was introduced in 
the test tube in such a way that the closed end of capillary 
remained below the surface of cone, sulp^ iuric acid and the open 
end of the tube remained above it. The test tube containing 
sulphuric acid was carefully heated uniformly through its surface 
by rotating the spirit lamp. The rise of mercury in the 
thermometer was noted from time to time. The temperature at 
which the Glucan sample melted to a clear liquid, was taken 
as its melting point. After noting the melting point the 
apparatus was allowed to cool at room temperature. 
3. CARBOHYDRATE ESTIMATICN 
Carbohydrate content of our glucan sample was estimated 
by using the method of Dubois et al. (1956). Glucose solution 
was used as the standard, 
(A) Preparation of standard solution: 
10 mg of glucose was dissolved in 100 ml of double 
distilled water. 
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(B) Preparation of Phenol Reagent: 
Phenol reagent was prepared by dissolving 8 gm of phenol 
in 100 ml of double distilled water. 
An 0.1 ml of immunomodulator sample, glucan or glucose 
solution, was brought upto 2 ml volume by the addition of 
distilled water. Then 1 ml of freshly prepared phenol reagent 
was added. Later, 5 ml of concentrated sulfuric acid (QS.SJIs) 
was added to "Uie above mixture. The tubes were shaken vigorously 
and cooled at room temperature. The colour intensity was read 
at a wave length of 490 nm by using a Bausch and Lomb Spectro-
nic-21 spectrophotometer, 
4, MEASUREMENT OF pH 
An ELICO L __ pH meter was used for a l l pH measure-
ments. Sodium t e t r abo ra t e (0 ,1 M, pW 9,18) and potassium 
hydrogen phosphate (0.05 M, pH 4,0) were used as standard 
buffer solut ions to c a l i b r a t e the pH meter. 
5, HYDROLYSIS 
Hydrolysis was carried out to determine the configuration 
of glucose units in the polysaccharide glucan. During hydro-
lysis of the polysaccharide, 1 gm portions of the test material 
were placed in 3 flasks and dissolved with fuming hydrochloric 
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acid at 0°C for 24 hours, diluted with iOO c.c of distilled 
water and heated on a steam bath for one hour. The solution 
was then cooled and diluted to 200 c.c with distilled water 
and filtered before taking the polarimetric readings. The 
specific rotations of the solution were taken at one, two and 
five hour intervals using a poiarimeter (ASCO Scientific 
Instruments, India), 
6. TOXICITY TEST 
It is essential to evaluate the potential toxicity of 
an adjuvant or immunomodulator before being brought into any 
therapeutic use. The toxic responses differ from species to 
species. It is not advisable to use a homogeneous strain 
(inbred strain) in toxicity tests, as the aim is to study new 
and unexpected effects of a substance in groups of animals of 
wider variability like random bred animals, A toxic effect 
that is seen in an animal model probably involves a coainon 
physiologic mechanism that is likely to be present in the 
humans, whereas such observations in one single species only 
indicates a particular effect in that species and is less 
likely to be present in another species. 
Generally, a fifty per cent end point experiment is 
done to determine the minimal lethal dose of the substance. 
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In toxicity determination experiments, the lethal dose is that 
amount of a substance which kills on an average about 50 per 
cent of the test animals. The determinatic«i of LD 50 doses 
of a substance involves administering different dose 
concentrations to several groups of animals and observing the 
number of animals in each group which are killed within 48 
hours of such administration. It is custcMnary to administer 
doses in an increasing logarithmic ratio (successively doubled 
doses)« Such doubling doses are given to each of the several 
animals which make up the experimental group. These 
experiments are so planned as to cover a complete range from 
a death to iOO per cent kill. But this is not the most 
economical use of the animals and if approximate toxicity 
of the preparation is known then the animals are divided into 
several groups, each receiving a dose supposed to be near or 
somewhat above/below the 50 per cent end point. Such a 
protocol fairly certainly ensures that in some groups the 
mortality will be higher, while in other groups it would be 
less than 50 per cent. In any screening program, toxicity 
tests on mice are usually performed first. 
In the present experiment 10 to 12 weeks old mice, each 
weighing between 12 to 15 gm were used. Mice were housed in 
metal cages and fed on pellet diet (Hindustan Lever Ltd,,India) 
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All mice were quarantined and acclimatised to laboratory 
conditions for at least seven days before experimentation. 
During this observation peroid, the mice which were less 
active or showed any other sign of abnormality were excluded 
from the study. The mice were divided into groups of five 
each and were placed in separate cages, mainly to select the 
dose ranges for the subsequent study. The glucan was adminis-
tered through a single intraperitonial inoculation. The 
dosages selected were 0.25 mg, 0.5 mg, 1,0 mg, 2,0 mg, 4,0 mg, 
8,0 mg, 16.0 mg, 32,0 rog, 64.0 mg and 128.0 mg respectively. 
The injected mice were observed continuously for two hours 
and then occasionally for further four hours, and were 
finally left overnight following which the mortality was 
recorded. One group of mice received only one single dose. 
One group containing 5 mice were kept as a control. Any test 
dose killing 50 per cent of mice in a group, was taken as an 
LD 50 dose, 
7. ADJUVANT DOSE RESPONSE STUDY 
To carry out the study of adjuvant dose response, 
rabbits were immunized with glucan in different concentrations, 
Sixteen rabbits were used in the experiment. All rabbits were 
quarantined and acclaimatised to laboratory conditions for at 
least one week before immunization. Rabbits were fed a pallet 
diet (Hindustan Lever Ltd,, India) a^ libitum. They had free 
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access to water. During this observation period, the animals 
which were less active or showed any other abnonaality, were 
exclud.ed from the study. The rabbits were then divided into 
four groups of four each and were placed in separate cages 
for subsequent immunization experiments. The rabbits in the 
first group were inoculated with 5% (w/v) dextrose only and 
were used as controls. The rabbit in the second, third and 
fourth groups were immunized, intraperitoneally, with 20 mg, 
40 mg and 60 mg concentrations of glucan respectively. Three 
doses were given in three weeks while fourth week was the 
list period. The fourth and the last dose inoculated in the 
fifth week was the booster dose. The entire immunization 
schedule was completed over a five week period in a total of 
4 doses. The antisera obtained from the immunized animals 
were used for checking the presence of specific antibodies 
against glucan samples. The immunization schedule is shown in 
Table I. 
8. INDIRECT HAEMAGGLUTINATION TEST (IHA) 
Indirect haemagglutination tests were carried out in 
the sera of immunized animals for checking the antigenicity of 
glucan. This test was done according to the method of 
Mathews et al, (1975) with few modifications. Microplates 
with U shaped bottom (Cook U-Plate, Cook Engineering Co,, 
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Alexandria, Virginia) were used for this test. Sheep red blood 
cells were washed four times in isotonic phosphate buffer 
saline, pH 7.2 by centrifugation for ten minutes at 1500 rpm. 
A 3% suspension of sheep RBC was prepared in isotonic F*iosphate 
buffer saline. The diluted RBC suspension was mixed with an 
equal volume of 1/20,000 tannic acid and incubated at 4 C for 
30 minutes with intermittent shaking. After incubation the 
suspension was centrifuged at 1200 rpm for 10 minutes and 
tanned sheep RBC's were washed three times with phosphate 
buffer saline containing 0»5% bovine serum albumin (BSA), 
The above was resuspended in p*iosF*Jate buffer saline 
containing bovine serum albumin to obtain a final concentra-
tion of 3% (v/v). The tanned sheep RBCs were sensitized with 
an equal volume of diluted glucan and incubated at ST'^C for 
30 minutes with intermittent shaking for obtaining a imiforo 
antigen coating of RBCs« After incubation they were centrifuged 
to remove the uncoated antigen supernatant. The pellet was 
washed 3-4 times with phosphate buffer saline containing 
bovine serum albumin. An 1,5^ (v/v) antigen coated RBC 
suspension was finally prepared for using it in the tests. 
To each well of the 'U' bottomed microtiter plate, 
0.025 ml of a serially diluted glucan antiserum was added 
along with an equal volume of antigen coated sheep RBC suspension. 
The plates were sealed with transparent gummed tape and gently 
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shaken for 5 minutes at room temperature. The plates were 
incubated at room temperature in humid chambers for 1 hour and 
then kept overnight at 4*^ 0. The highest dilution of the test 
serum giving a positive carpet like pattern was recorded as 
the titration end point. Negative reactions were detected 
by the formation of a compact button with entire margin. 
j R E : s t J i - - T s ; 
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RESULTS 
ISOLATION OF ^-i,3 GLUCAN 
p-i,3 Giucan, a cell wall component of S» cerevisae. 
was extracted to obtain a better yield and purified. The 
procedure devised for isolation of p-i,3 Giucan resulted in 
an overall yield of 7,4 per cent of the weight of compressed 
yeast. The yield was somewhat on the lower side owing to 
inadvertent experimental losses during fractionation. During 
fractionation with ethyl alcohol, some oily droplets were 
observed in the filtrate. A plot depicting the comparative 
yield of giucan obtained by earlier workers is shown in 
Figure i. 
MELTING POINT 
The temperature at which the isolated giucan began to 
melt to a clear liquid was read as i3i°C, This was taken as 
the melting point of the giucan extracted in this study. 
The melting point of giucan as determined in this and other 
studies is shown in Figure 2, 
CARBOHYDRATE CONCENTRATION 
The carbohydrate concentration of the isolated giucan, 
estimated by the method of Dubois et a^. (1956) was estimated 
as 240 mg/ml. Carbohydrate estimation graph is shown in 
Figure 3, 
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HYDROLYSIS 
The specif ic ro ta t ions of the di luted hydrolysed poly-
saccharide solut ions were taken a t one, two and f ive hour 
i n t e r v a l s . The speci f ic r o t a t i o n s , (o<:)_ a t d i f ferent 
in te rva l s were -K3.47°, +1.02° and +1.50° respec t ive ly . The 
upward mutorotation during hydrolysis indicated a 
p-configuration of the glucose uni t s in the polysaccharide 
glucan. 
TOXICITY TEST 
The data , morta l i ty graph and animal t i t r a t i o n r e s u l t s , 
presented in t h i s study was analyzed as fol lows. The dose 
given in milligrams to an experimental animal were converted 
in to log dose and plot ted along the X-axis on a grap*i paper. 
Per cent morta l i ty in each group a t various doses was 
converted in to probi ts and plot ted along the absc i s sa . The 
curve was extrapolated according to the method of l e a s t 
squares . The LD 50 was obtained from the grapJh by finding 
out the log dose a t probit 5 , The experimental curve gave 
an LD 50 dose at 31.6 mg. Thus for a mice the LD 50 dose was 
g rea te r than 2 g/kg upon i n t r a p e r i t o n i a l inocula t ion . The 
log-dose probit response for morta l i ty per cent l e t h a l 
response to glucan i s shown in Figure 4 . 
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TABLE I I 
Animal T i t r a t i o n of a T o x i n / Immunomodulator Glucan, 
Dose 
(mg) 
0.25 
0.5 
i.O 
2.0 
4.0 
8.0 
16.0 
32.0 
64.0 
128.0 
Total No. 
of mice 
5 
5 
5 
5 
5 • 
5 
5 
5 
5 
5 
survivor 
(Number) 
5 
5 
4 
5 
5 
4 
4 
3 
1 
0 
Dead 
(Number) 
0 
0 
1 
0 
0 
1 
1 
2 
4 
5 
Percent 
mortality 
0 
0 
20 
0 
0 
20 
20 
40 
80 
100 
8 
7 
CD 
O 
cr 3 
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1 2 3 
Log Dose of G lucan / M ice ( i p ) 
F I G . ^ - L O G DOSE PROBIT RESPONSE FOR MORTALITY 
PERCENT LETHAL RESPONSE TO GLUCAN 
69 
INDIRECT HA£MAGGLUTINATION(IHA) TEST 
Rabbits immunized with glucan showed markedly increased 
antibody levels compared to control rabbits given only 5% 
(w/v) dextrose. The highest IHA titers in experimental 
group III inoculated with glucan at 40 mg/kg body weight was 
recorded in the fourth and the sixth week. Group III animals 
showed approximately a 3 fold increase in antibody level 
compared to group IV. Serum samples of control rabbits 
given only 55^  (w/v) dextrose were negative. A titer value 
of Less than 64 was considered negative. The detailed IHA 
results are shown in Table III, 
TABLE III 
IHA Titers in Rabbit Sera 
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Animal Groups IHA Titers 
4th week 6th week 
II 
(20 mg/kg Glucan) i : 512 1 : 1024 
III 
(40 mg/kg Glucan) 1 : 4096 i : 16384 
IV 
(60 mg/kg Glucan) i : 2048 1 ; 4096 
An IHA Titer less than 64 was taken as negative. 
E>xsczTjrss loisr 
c:oisrc:i^ursi i oisr 
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DISCUSSION 
Glucan, a p-i,3 polygiucose isolated from the inner 
cell wall of S. cerevisae, is a well recognized immunoaodula-
ting agent (Di Luzio et al. 19 63, 1976). Glucan for its 
immunomodulating role has been a subject of continued interest 
and study for the past several years. The investigations and 
the findings presented in this thesis are chiefly based on 
studies pertaining to the isolation, toxicity and adjuvan-
ticity of p-1,3 Glucan. Such studies relating to the 
toxicity of glucan are not too many as to allow a wide 
comparison of the numerous reports claiming its efficacy in 
the stimulation of reticuloendothelial system, iiraaunologic 
and hemopoietic functions. All previous reports show 
disparities in the biological activity of various glucan 
preparations. In particular, the effect of glucan has been 
reported to depend more on the batch (lot) and/or source used 
(Suit et al, 1978). In this study glucan was prepared as 
per the modified method of Di Luzio et al. (1979) and Hassid 
et al. (1941). An attempt was made to standardize the 
preparation for obtaining a sample with uniform immunobiological 
activity within the various lots. It was considered necessary 
tp eliminate the problem of glucan-associated biological 
variance. Such standardization is essential in view of its 
n 
possible use in future vaccination studies, as also for 
obtaining consistently uniform results in any future attempts 
towards development of an effective vaccine against parasitic 
infections. The usual practice in the past was that most of 
the investigators were able to obtain glucan from one or two 
laboratories in Europe and United States for carrying out the 
immune studies against parasitic infections such as 
Amoebiasis, Leishmaniasis, etc. 
But more recently numerous attempts have been made 
to isolate glucan from s. cerevisae for use in various 
laboratories. Hassid et al. in 1941 were the first to isolate 
glucan with a total yield of 6A% of the weight of the 
compressed yeast. Peat et al. in 1958 made an attempt to 
isolate glucan from S. cerevisae. The yield obtained was 
very low of about 0.65^ of the weight of compressed yeast. 
Then Manners et al. (1973) isolated glucan from s. cerevisae 
and the yield obtained was 2.4^ of the weight of compressed 
yeast. Finally, in 1979 Di Luzio et al. with the modification 
of the procedure of Hassid et al, were able to isolate glucan 
with a better yield 6.8^ of the weight of compressed yeast. 
Our results clearly indicate that glucan can be successfully 
isolated for individual use in laboratories by adopting 
certain modifications in the procedure employed by previous 
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workers. We were a lso able to increase the yie ld to a ce r t a in 
extent . The yie ld of glucan in t h i s study was 7.4^. This 
y ie ld was approximately 0,65li higher than what Di Luzio e t a l , 
(1979) obtained using t h e i r procedure. The exact reason for 
' t h i s difference in the yield may be due t o the r epe t i t ion of 
a few steps and ce r t a in modifications such as employing 
buchner funnel f i t t e d with 0,45 jum Whatman f i l t e r paper during 
f i l t r a t i o n by suc t ion . In addi t ion to t h i s , we employed a 
procedure for alcohol extract ion of glucan with ethyl alcohol 
and t h i s was repeated un t i l the alcohol f i l t r a t e was essen-
t i a l l y colourless and no oily drople ts were seen. By 
repeating t h i s s t ep , t he re was a complete el imination of 
organic solvent soluble substances. The use of 0.45 jam 
Whatman f i l t e r paper has saved inadvertent experimental 
losses of glucan pa r t i cu l a t e during f r ac t iona t ion . 
After estimating the melting point of the i so la ted 
glucan as 131°C ^ chemical analysis was carr ied out for the 
t o t a l carbohydrate content according t o the procedure of 
Dubois et a l . (1956), The confirmation of ^-configuration 
of glucose uni t s in the i so la ted polysaccharide glucan was 
assayed by reading specif ic ro ta t ions (cx) D during hydrolysis 
a t d i f fe ren t i n t e r v a l s . The upward mutorotation indicated 
a p-configurat ion. The r e s u l t s thus reported were found to 
be in complete agreement with the r e su l t s obtained by e a r l i e r 
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workers such as Hassid et al. (1941), Peat et al. (1958) and 
Manners et al, (1973), 
These studies were also focused on the evaluation of 
any available toxicity of the isolated glucan. Such a study 
was undertaken because of the reported differences in the 
biological activity of various glucan preparations depending 
on the batch/lot and/or the source material used. Surprisingly, 
few therapeutic indices have been recorded to date, and it 
is almost impossible to establish the toxicity of some of 
these compounds. The simplest estimation of toxicity, which 
involves recording of change in the body weight over a 
short period following adjuvant administration are rarely if ever 
reported, unfortunately, this information cannot be established 
readily from published LD 50 data, as almost invariably 
several routes of administration or varying conditions of 
stress have been employed to determine the lethal dose. The 
nature of the animal species studied is very important in 
this context, FCA has also been a widely used immunoadjuvant, 
The FCA treated animals were found more predisposed to skin 
lesions. Histologically, perivascular cuffing with mono-
nuclear cells were found in the initial phase (Freund, 1953), 
More recently, the toxic properties of cord factor has been 
studied to a certain extent. Cord factor is toxic for mice 
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when administered in iOjl^  emulsions of paraffin oil in repeated 
injections. Toxicity of cord factor depended on the size 
disttibution of oil droplets (Bekierkunst, 1977), IJQ vivo 
and ^  vitro studies indicate that cord factor causes the 
structural disintegration of mitochondrial membrane, leading 
to specific inhibition of oxidative phosphorylation ^Kato et al. 
1978). This study thus eliminated the doubts regarding 
glucan-associated immunobiological variance, if any, for its 
future use in vaccination studies which must be carried out 
in order to evaluate its potential effectiveness. One 
benefit of such a study was to reduce the risk of lethality 
generally believed to be exerted by glucan to the immune 
system following immunization. This study also helped in 
establishing a correct dose pattern to evaluate the adjuvan-
ticity. However^ such observations in one species only 
indicate a particular effect in that species and less 
likely to be present in another species. Our results clearly 
indicate that the LD 50 dose of glucan, i.e. the dose of glucan 
which would kill on an average 50 per cent of the test 
animals, was found to be greater than 2 gm/kg for mice when 
given intraperitoneaily. This LD 50 value reflects the limit 
raage for the safe use of glucan. The LD 50 values obtained 
here, are in agreement with the results obtained by patchen 
et al. (1980, 1983) and Cook et al. (1980), 
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The extensive and varied review regarding the broad 
spectrum activity of immunophannacologic activities of 
adjuvant glucans are well documented. These and other similar 
studies only demonstrate the growing interest in these unique 
molecules. Since the end metabolite is glucose, a new 
dimension in pharmacology and therapeutic uses employing this 
newer molecule is clearly indicated, Giucan has been shown 
to have significant effects upon humoral immunity (Wooles and 
Di Luzio, 1962) and cell mediated immunity (Wooles and 
Di Luzio, 1962), Administration of giucan is usually associa-
ted with enhanc«nent of macrophage/monocyte cell series, with 
a corresponding increase in the activity of reticulo«ndothelial 
system (Wooles and Di Luzio, 19 63). Giucan has been shown to 
enhance host resistance to a variety of experimentally 
induced bacterial (Reynolds et al., 1980), fungal (Williams 
et al,, 1978), viral (Reynolds et al., 1980; Williams and 
Di Luzio, 1980) and parasitic (Cook et ai», 1980) diseases. 
It was also shewn that intraperitoneal administration of 
giucan significantly modified the course of E» coli sepsis in 
mice (Williams et al,, 1983), Giucan was also found to 
exhibit a strong adjuvant effect when inoculated intravenously 
with killed erythrocytic stages of P. berghei. Mice pretreated 
with dead parasite and giucan showed 100 per cent survival 
after challenge, as opposed to 29 per cent survival of mice 
pretreated with dead parasites. Holbrook et al. (1981) 
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through their studies demonstrated that the mice which received 
glucan only were all dead following challenge. Patchen and 
her group have extensively studied the influence of glucan 
on murine pluripotent stem ceils, and on myeloid and 
erythroid progenitor cells. In a series of extensive studies, 
Patchen demonstrated that following i.v, administration of 
glucan in the dose range of 0,1-2,0 mg per mouse, the proli-
feration of bone marrow and splenic pluripotent stem cells, 
splenic macrophage and granulocyte-macrophage colony forming 
cells, and splenic erythroid colony and burst-forming cells 
were stimulated in a direct, dose dependent manner. The 
molecular mechanisms through which glucan mediates its 
stimulatory effects on hemopoiesis are still largely 
unknown (Patchw et al,, 1983), But now there are increasing 
evidences to suggest that immune enhancement and protection 
by glucan is macrophage mediated, Immuno-amplification by 
glucan is further supported by the data obtained from 
experiments showing complete loss of protection to E, coli 
infection in glucan treated mice which were subsequently 
given a macrophage suppressant (William et al., 1983). 
Deimann and Fahimi (1979) observed that glucan induced a dose 
dependent accumulation of macrophages in the liver. By 
scanning electron microscopy, as well as histochemistry, 
the derivation of kupffer cells, which are present in massive 
K^' 
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numbers in the liver of glucan - treated animals was thought 
to arise mainly from bone marrow and to a minor extent 
through self replication in situ> In our studies for 
assessing the adjuvanticity of isolated glucan, the rabbits 
were inoculated with 20 mg/kg, 40 mg/kg and 60 mg/kg doses 
respectively, A total of four doses were given in five 
weeks time. Our results clearly indicate that the antibody 
titers as evaluated by IHA were found to be highest with 
40 mg/kg dose. The results thus obtained correspond with 
the work of Patchen et al. (1983) on dose dependent responses 
of immunomodulating agent , Glucan, 
While concluding the results based on this study, we 
can say that the isolated material from bakers yeast, 
S. cerevisae, is a polyglucose ^1,3 glucan, capable of 
enhancing the immune responses in a variety of host animals* 
The results of t^is study are comparable with the results of 
numerous other workers who used glucan in their researches. 
Ultimately, such studies will be helpful in eliminating the 
doubts regarding glucan associated biological variance as 
glucan is going to be increasingly used in the coming years 
for enhancing the inanune responsiveness against a large 
number of parasitic antigens in susceptible hosts. 
B X EML. I C:><SI^A.r>M Y 
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